An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod

OBJECTIVES: To evaluate the changes in disease-related biomarkers and safety of paquinimod, an oral immunomodulatory compound, in patients with systemic sclerosis (SSc). METHODS: In this open-label, single-arm, multicenter study, SSc patients with a rapidly progressive disease received paquinimod fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hesselstrand, Roger, Distler, Jörg H. W., Riemekasten, Gabriela, Wuttge, Dirk M., Törngren, Marie, Nyhlén, Helén C., Andersson, Fredrik, Eriksson, Helena, Sparre, Birgitta, Tuvesson, Helén, Distler, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325221/
https://www.ncbi.nlm.nih.gov/pubmed/34330322
http://dx.doi.org/10.1186/s13075-021-02573-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325221/
https://www.ncbi.nlm.nih.gov/pubmed/34330322
http://dx.doi.org/10.1186/s13075-021-02573-0

Ejemplares similares